Introduction {#s1}
============

Lung cancer, in which about 80% of cases are identified as non-small cell lung cancer (NSCLC), is regarded as the leading cause of cancer-related death in the world ([@B1]). Alterations associated with specific genes, such as epidermal growth factor receptor (*EGFR*) or anaplastic lymphoma kinase (*ALK*), contribute to the development and progression of lung cancer. Relevant targeted therapies directing against these driver gene mutations have achieved successful clinical outcomes ([@B2], [@B3]). The *EGFR* driver mutations are known to be prevalent among Asian NSCLC patients ([@B4]). Although *EGFR* tyrosine kinase inhibitors (TKIs) could improve the objective response rate (ORR) and progression-free survival (PFS) of *EGFR* mutated patients, acquired resistance is inevitable and often occurs after 9--14 months of therapy ([@B5]). Although the administration of third-generation EGFR-TKIs targeting the *EGFR T790M* mutation, such as Osimertinib, has shown promising outcomes ([@B6]), acquired resistance still exists ([@B7]). Thus, novel effective treatment strategies remain urgently needed.

Recently, immune checkpoint blockades (ICBs), including anti-programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) blockades, have been demonstrated to robustly enhance anti-tumor immunity in patients with a wide range of cancers, especially with NSCLC ([@B8], [@B9]). Despite the sustained response of ICBs in NSCLC, the clinical efficacy of anti-PD-1/PD-L1 blockades in *EGFR* mutated NSCLC patients has been reported to be moderate compared with those without *EGFR* mutations ([@B10], [@B11]). Moreover, results from several clinical trials indicated that the combination therapy of EGFR-TKIs and ICBs led to a high incidence of treatment-related adverse effects ([@B12]). As a result, immune checkpoint blockades have been excluded from daily clinical applications for NSCLC patients with *EGFR* driver mutations. Nevertheless, some *EGFR* mutated lung cancer patients enrolled in clinical trials could still respond to ICB therapy. Therefore, it is necessary to characterize the underlying mechanism and identify prognostic biomarkers for predicting clinical benefits with anti-PD-1/PD-L1 blockade therapy in this specific NSCLC subpopulation.

Unlike tumor-associated antigens (TAA), which are found both in tumor cells and normal tissues, tumor neoantigens are exclusively processed by tumor cells and presented by major histocompatibility complex (MHC) molecules. Individual MHC:peptide complex can be recognized by T-cell receptor with high specificity ([@B13], [@B14]). This mechanism provides promising targets for personalized immunomodulatory therapy such as cancer vaccine and adoptive T-cell transfer therapy ([@B15], [@B16]). Interestingly, previous reports suggested that neoantigens can be served as the targets of highly specific and durable anti-tumor immunity ([@B17], [@B18]), and neoantigen-specific T-cell response can be identified in patients benefitting from ICBs. Neoantigens derived from *EGFR* mutations have been reported in preclinical study ([@B19]), but it remains confusing whether *EGFR* driver mutations could generate true neoantigens in suppressive tumor microenvironment (TME).

With the development of next-generation sequencing (NGS) technologies and bioinformatics algorithms, neoantigen can be successfully identified *in silico* in many solid tumors ([@B20]). Monitoring neoantigen-specific T-cell response to anti-PD-1/PD-L1 blockades in peripheral blood has become a feasible way to predict the prognosis of cancer patients ([@B13], [@B21]). Nevertheless, only a small amount of neoantigens were identified to be truly immunogenic, and clinical applications based on neoantigens are still in its infancy stage ([@B17]). Given the current limiting treatment options for NSCLC patients after EGFR-TKI resistance, novel personalized therapeutic strategies based on T-cell immunity to neoantigens could improve clinical outcomes when candidate neoantigens are available.

Here, we reported an advanced NSCLC patient with *EGFR* driver mutations achieved durable clinical benefits from Nivolumab monotherapy. By conducting whole-exome sequencing (WES), RNA sequencing (RNA-seq), and TCR sequencing, we were able to depict a comprehensive landscape of genomic alterations and predict candidate neoantigens from tumor tissue obtained before the initiation of Nivolumab. We also successfully validated anti-tumor immunity to some high-quality neoantigens *in vitro*, including two derived from *EGFR* driver mutation. These results displayed that immune checkpoint blockades could elicit robust endogenous T-cell response to clonal neoantigens generated from driver mutations. Our findings may provide clinical evidences that ICBs should not be completely excluded from therapy options for NSCLC patients after the failure of EGFR-TKIs. Furthermore, personalized immunomodulatory therapy targeting specific clonal neoantigens should be developed for clinical practice in the future.

Result {#s2}
======

Case Presentation
-----------------

A 34-year-old male patient suffered from chest and back pain in January 2017. Radiological examinations revealed a 65-mm nodule in the middle lobe of the right lung, several metastatic pulmonary nodules in both lungs, and multiple bone lesions. The patient underwent a bronchoscopy biopsy, and pathological examination revealed lung adenocarcinoma with *EGFR* exon 19 deletion (*EGFR 19del*). His clinical stage was T4N2M1b stage IV ([Figure 1A](#F1){ref-type="fig"}). The patient was initially treated with Icotinib from February 2017 until progression occurred in July 2017. Additionally, intensity-modulated radiation therapy (IMRT) targeting bone metastases in the lumbar spine, pelvic cavity, and left femur were given with a total dose of 36 Gy in 12 fractions. After that, he was administered with Pemetrexed plus Nedaplatin for four cycles and Pemetrexed for another one cycle until progression occurred in November 2017. After systemic chemotherapy, he turned to traditional Chinese medicine treatment, until the onset of brain metastases in the right frontal lobe and left basal ganglia in June 2018 ([Figures 1B,C](#F1){ref-type="fig"}).

![Durable clinical response to Nivolumab in a non-small cell lung cancer (NSCLC) patient with epidermal growth factor receptor (*EGFR*) driver mutations. **(A)** Clinical timeline of patient, with major treatment indicated. The patient has been benefitting from immunotherapy for more than 19 months. **(B)** Chest computed tomography (CT) of the metastatic lung tumors before Nivolumab initiation (June 2018) and last time follow-up (January 2020). **(C)** Magnetic resonance imaging (MRI) before and after Nivolumab treatment. Images in the middle revealed an increased size of the left basal ganglia lesion accompanied by edema and multiple brain nodule metastases. A rapid decrease in lesions was noted in the following radiological evaluations.](fimmu-11-01366-g0001){#F1}

The patient was, thereafter, enrolled in a phase 3 clinical trial for Nivolumab monotherapy (NCT03195491). Regardless of PD-L1 and tumor mutational burden (TMB) status, this trial enrolled advanced lung cancer patients who failed previous systemic therapies. Biopsy of tumor sample obtained before Nivolumab initiation indicated *EGFR T790M* mutation. The patient presented with dizziness after two cycles of Nivolumab administration in August 2018, and magnetic resonance imaging (MRI) scans showed an increased lesion size and edema of the left basal ganglia, as well as multiple brain metastases ([Figure 1C](#F1){ref-type="fig"}). After dehydration therapy with Mannitol, Nivolumab was reinitiated for another two cycles. According to RECIST 1.1 Criteria, he achieved partial response (PR) with decreased tumor size of lung and brain metastases in September 2018. After 10 cycles of Nivolumab treatment, the patient experienced hypothyroidism with elevated levels of TSH and decreased levels of both FT3 and FT4, and treatment with Levothyroxine was applied to relieve the symptoms. Generally, Nivolumab was well-tolerated. Currently, the patient receives an intravenous infusion of Nivolumab at 240 mg every 2 weeks. Based on the follow-up examinations, the patient has achieved PR for more than 1 year.

Comprehensive Analysis of Genome and Immune Landscape
-----------------------------------------------------

Of the tumor analyzed, a PD-L1 tumor proportion score (TPS) of ≥50% was revealed ([Figure 2A](#F2){ref-type="fig"}). Based on sequence data, tumor mutational burden (TMB) was 6.00 muts/Mb, and tumor neoantigen burden (TNB) was 2.67 neos/Mb. Peripheral blood mononuclear cells (PBMCs) collected before Nivolumab initiation and thereafter every 2 months were investigated by TCR sequencing. We selected T-cell clones with a frequency of ≥10^−3^ to investigate the dynamic TCR changes. The maintenance of most high-frequency clones was detected ([Figures 2B,C](#F2){ref-type="fig"}). Only one high-frequency clone decreased sharply after 2 months of Nivolumab therapy. This may partly explain the pseudoprogression after four cycles of Nivolumab treatment in August 2018 and durable clinical response throughout the whole study.

![Comprehensive analysis of the immune landscape. **(A)** Immunohistochemistry (IHC) image with anti-programmed cell death-ligand 1 (PD-L1) antibody (Dako IHC 22C3 platform). Microscope magnification 400×. A PD-L1 tumor proportion score (TPS) of ≥50% was detected. **(B)** Maintenance of the high-frequency T-cell clones throughout Nivolumab treatment. TCR-seq was conducted on PBMCs collected pre and post Nivolumab treatment. T-cell clones with a frequency of ≥10^−3^ in the baseline are shown. Each line represents one clone. **(C)** Representative TRBV--TRBJ junction circos plots. Bands represent different V and J gene segments. Ribbons imply V/J pairings. The width of the band is proportional to the usage frequency.](fimmu-11-01366-g0002){#F2}

Prediction and Validation of Immunogenic Neoantigens
----------------------------------------------------

To evaluate potential factors contributing to the durable response of the patient, we followed a restricted pipeline integrating NGS technology and validation experiment aiming at identifying true neoantigens. According to WES results of lung tumor samples, 84 somatic non-synonymous mutations were identified, and 28 of them were likely to bind to the corresponding HLA alleles with high affinity (IC50 \<500 nmol/L) ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). A total of six genes were found to be truly expressed at the transcript level, including *EGFR, TP53, POLA2, AP2AM1, DENND6B*, and *TTC37*. Ultimately, 13 HLA-A^\*^11:01-restricted candidate neoantigen peptides generated from these six genes were selected for further analysis. Furthermore, clonal neoantigens can be derived from *EGFR, TP53*, and *DENND6B* mutations, whereas *POLA2, AP2AM1*, and *TTC37* mutations could only generate subclonal neoantigens ([Table 1](#T1){ref-type="table"}). Then, both mutant and wild-type peptides were synthesized and tested by IFN-γ ELISPOT assay to validate the immunogenicity of these neoantigens. As a result, 4 out of 13 mutant peptides could elicit a strong response, whereas the wild-type counterpart generated no significant response. Besides, there were no notable T-cell responses to subclonal neoantigens ([Figure 3](#F3){ref-type="fig"}).

###### 

HLA-A[^\*^](#TN1){ref-type="table-fn"}11:01 restricted candidate neoantigens validated in IFN-γ ELISPOT assay.

                                                        **Mutant peptide**   **Wild-type peptide**                 
  ----------------------- ---- --------- -------------- -------------------- ----------------------- ------------- ----------
  Clonal neoantigens      C1   EGFR      E746_A750del   IPVAIKTSPK           131.9                   IPVAIKELRE    28,185.9
                          C2   EGFR      E746_A750del   AIKTSPKANK           404.4                   AIKELREATS    37,251.5
                          C3   TP53      A161T          RVRAMTIYKQ           288.6                   RVRAMAIYKQ    486.1
                          C4   TP53      A161T          GTRVRAMTIYK          165.5                   GTRVRAMAIYK   251.6
                          C5   TP53      A161T          TRVRAMTIYK           30.7                    TRVRAMAIYK    44
                          C6   TP53      A161T          RVRAMTIYK            16.1                    RVRAMAIYK     20.9
                          C7   DENND6B   R398Q          QLLKGVQKK            498.5                   RLLKGVQKK     165.1
                          C8   DENND6B   R398Q          KALLKQLLK            54.8                    KALLKRLLK     71.5
                          C9   DENND6B   R398Q          KQLLKGVQK            420.6                   KRLLKGVQK     17,851.5
  Subclonal neoantigens   S1   AP2M1     V377M          KASENAIMWK           51.6                    KASENAIVWK    91.8
                          S2   AP2M1     V377M          ASENAIMWK            41.6                    ASENAIVWK     68
                          S3   POLA2     E448K          FSYSDLSRK            47.3                    FSYSDLSRE     15,881.9
                          S4   TTC37     D95A           KDALPGVYQK           171.6                   KDDLPGVYQK    7,311.9

*HLA-binding affinities for peptides, predicted by NetMHCpan v3.0. Peptides with an IC50 \<500 nM can be regarded as major histocompatibility complex (MHC) binders*.

![Immunogenicity of candidate neoantigens. **(A,B)** Representative images from IFN-γ ELISPOT assay. Peripheral blood mononuclear cells (PBMCs; 2 × 10^5^ per well) from the patient were stimulated for 10 days with individual peptides in the presence of cytokines (IL-2, IL-7, and IL-15) and were stimulated again on day 10. T-cell reactivity was assessed by IFN-γ ELISPOT assay. **(C)** Bar graph showing IFN-γ ELISPOT assay data. PBMCs stimulated with no peptide were regarded as negative controls (NC). At least two independent experiments were done in triplicate. ^\*^*p* \< 0.05.](fimmu-11-01366-g0003){#F3}

The Dynamic Change of TCR Repertoire After Neoantigen Stimulation
-----------------------------------------------------------------

Although IFN-γ ELISPOT assay could reveal the reactivity between immunogenic neoantigens and autologous T cells, we utilized TCR sequencing to further confirm whether T cell responded to neoantigens. Owing to the limited amounts of PBMCs, we only validated the above 4 out of 13 neoantigens generated from *EGFR 19del, TP53 A161T*, and *DENND6B R398Q* mutations.

After stimulating PBMCs with neoantigens, the frequency of some T-cell clones stimulated by mutant peptides was much higher than those clones stimulated by corresponding wild-type peptides. These clones were defined as significant clones, which may specifically recognize neoantigens ([Supplementary Table 2](#SM2){ref-type="supplementary-material"}). Matching significant clones to those found in blood samples, 18 clones remained at high frequency during this study, and 7 clones could only be detected after the initiation of Nivolumab ([Supplementary Figure 1](#SM3){ref-type="supplementary-material"}).

Discussion {#s3}
==========

Owing to the limited therapeutic strategies for NSCLC patients acquired resistance to EGFR-TKIs, it may be tempting to begin immune checkpoint blockades therapy for its well tolerance and low toxicity. Some retrospective studies suggest that *EGFR* mutated NSCLC cannot benefit from anti-PD-1/PD-L1 blockade therapies ([@B10], [@B11]). However, long-term follow-up of these clinical trials and some case reports showed that a group of *EGFR* mutated NSCLC patients sustained a durable response. Most studies focused on elucidating the underlying mechanism of the negative clinical outcomes ([@B22]--[@B25]). Little efforts have been made to stratify a small group of patients with *EGFR* driver mutation, who are likely to benefit from immunotherapy. To our knowledge, this is the first report on assessing the predictive biomarker from the perspective of neoantigens in an *EGFR* mutated NSCLC patient receiving Nivolumab. Our results may provide clinical evidences for the potential application of immune checkpoint blockades in NSCLC patients with acquired resistance to EGFR-TKIs.

PD-L1 expression is employed as a general biomarker for immune checkpoint blockade treatment ([@B26]). Previous studies demonstrated that EGFR signaling pathway could intrinsically upregulate tumor PD-L1 expression and contribute to the immune escape of *EGFR* mutated NSCLC ([@B10]). Conversely, real-world studies showed a higher expression level of PD-L1 in *EGFR* wild-type NSCLC ([@B27], [@B28]). A recent study manifested that the proportion of PD-L1-positive tumors in patients receiving EGFR-TKIs tended to be increased after EGFR-TKI therapy ([@B29]). As a result, these contradictory results cannot fully explain the relationship between EGFR signaling pathway and PD-L1 expression. Our patient had a PD-L1 tumor proportion score (TPS) of ≥50%, which may contribute to his durable response to ICBs. For both *EGFR* mutated and wild-type NSCLC in the ATLANTIC trial, patients with higher tumor PD-L1 expression can achieve a better objective response from Durvalumab treatment ([@B29]). However, some patients with high PD-L1 expression failed with immunotherapy unexpectedly ([@B30]). The opposite results revealed that PD-L1 expression may not be a reliable predictive biomarker for NSCLC with *EGFR* driver mutations receiving immunotherapy, and new effective biomarkers are still needed.

Currently, tumor mutational burden (TMB) is considered as a positive prognostic factor for ICBs ([@B31]). Patients with high TMB could have better objective responses to anti-PD-1/PD-L1 blockades compared with those with low TMB ([@B14]). Similarly, tumor neoantigen burden (TNB) describes those mutations at the transcript level or protein level and is supposed as the surrogate of TMB. However, some researches showed that patients with high TNB may still be resistant to ICBs ([@B32]). On this account, identifying high-quality neoantigens could optimize the prediction of pre-existing immunity to tumors and boost the effect of ICBs for proper immunosurveillance ([@B33]).

We presented a pipeline combining *in silico* and *in vitro* approaches to identify true neoantigens. Neoantigens expressed by a large proportion of tumor cells were defined as clonal neoantigens ([@B34]). In contrast, subclonal neoantigens may be generated during tumor evolution, which mediated immune escape and facilitated tumor invasion ([@B35]). In this study, we only successfully detected T-cell response to clonal neoantigens in IFN-γ ELISPOT assay, which could partly be explained by the loss of subclonal neoantigens after Nivolumab treatment ([@B36]). Here, a total of four clonal neoantigens, including two arising from *EGFR 19del*, 1 from *TP53 A161T*, and 1 from *DENND6B R398Q*, respectively, were validated in this case. Although immunotherapy targeting *EGFR* mutations have been widely discussed ([@B34]), there was no research on identifying neoantigens generated from *EGFR* mutations in NSCLC patients. Neoantigens derived from hotspot mutations of *TP53*, the most frequently altered gene across solid tumors, have already been screened for novel therapeutic approaches ([@B35]). *TP53 A161T*, which is present in approximate 0.06% of cancer patients ([@B37]), remained uncharacterized, and future exploration is warranted. Additionally, the role of *DENND6B* in tumors is largely unknown. Based on our results, we speculated that neoantigens derived from driver mutations facilitated clinical benefit in patients treated with immune checkpoint blockades. Therefore, *EGFR* mutated NSCLC patients could be recommended to choose anti-PD-1/PD-L1 blockades in the presence of clonal neoantigens derived from driver mutations with high immunogenicity.

Previous studies had shown that memory T cells from peripheral blood could respond to neoantigens in tumor tissue ([@B38]), and CD8^+^PD-1^+/high^ T-cell subsets were preferentially enriched upon neoantigen stimulation ([@B39], [@B40]). Analyzing features of CD8^+^ T cells seemed to be an alternative choice for monitoring immune response. Our former research had already identified the peripheral blood TCR repertoire of NSCLC patients as a useful prognostic biomarker ([@B41]). In this study, we investigated the dynamic change in TCR frequencies and found that the maintenance of high-frequency T-cell clones might be associated with a durable response to Nivolumab. By comparing each T-cell clone after neoantigen peptide stimulation, we identified some neoantigen-specific T-cell clones, which are likely responsible for the recognition of MHC:peptide complex. A recent study has raised the hypothesis of clonal replacement after immunotherapy, and researchers founded that expanded T-cell clones were recruited from blood rather than continuously presented in tumors ([@B42]). Consistent with the hypothesis, we observed that some significant clones only expanded after the initiation of Nivolumab. Further research should be conducted to characterize the anti-tumor immunity of these T-cell clones.

Besides tumor-intrinsic factors, tumor microenvironment (TME) will also affect the efficacy of immunotherapy. A newly published research focused on TME found that *EGFR* driver gene alterations, despite its inescapable role in tumor growth, contributed directly to a non-inflamed phenotype, with high regulatory T-cell (Treg) infiltration and low CD8^+^ T-cell infiltration ([@B27]). For our patient, Nivolumab was initiated only after multiline therapies, including EGFR-TKIs, chemotherapy, and radiotherapy. Thus, we presumed an enhanced suppressive activity of TME, and we did not conduct a comprehensive analysis on TME.

The clinical implications of our research were profound. A previous study showed that the anti-EGFR antibody titer was characterized as highest in NSCLC patients with *EGFR* exon 19 deletion, suggesting that this mutation is immunogenic and can be expressed at protein level ([@B43]). We may infer that the peptide sequences derived from *EGFR* exon 19 deletion (IPVAIKTSPK, AIKTSPKANK) may be a potential therapeutic target of cancer vaccine for NSCLC. Moreover, HLA-A^\*^11:01 was the most frequent HLA-A allele in Asians ([@B44]). *EGFR 19del* is the most common mutation in *EGFR* mutated NSCLC patients, accounting for \~45% of all cases ([@B43]). Consequently, it is reasonable that our results can provide important clinical data for a subgroup of NSCLC patients with both *EGFR* mutations and HLA-A^\*^11:01 allele.

There are some expected limitations of our study. At first, TCR profiling was only performed on peripheral blood and cultured PBMCs due to a lack of tumor tissue. A mapping of TCR in tumor and metastatic sites will make the results more convincing. Second, recent research has highlighted the important role of MHC class II-restricted neoantigens in the anti-tumor response ([@B45]). In this study, we only focused on MHC-I-restricted neoantigens. Investigations of MHC class II-restricted neoantigens may be carried out in the future with more advanced technologies.

Overall, our data suggested that high-quality neoantigen can be generated from *EGFR* driver mutation. ICBs can be used for advanced NSCLC with acquired resistance to EGFR-TKIs in the context of specific clonal neoantigens with high immunogenicity. Monitoring of neoantigen-specific T-cell response might be beneficial for improving the survival rate of NSCLC patients. Personalized immunomodulatory therapy targeting these neoantigens should be explored for better clinical outcomes. We hope our findings may help pave the way for future researches on *EGFR* mutated NSCLC.

Materials and Methods {#s4}
=====================

Patient Samples
---------------

Peripheral blood was obtained from the patient before the initiation of Nivolumab and every 2 months after treatment. PBMCs were isolated by Ficoll-Hypaque density centrifugation and were analyzed immediately after isolation. Lung cancer tissue sample was obtained by computed tomography (CT)-guided lung biopsy before Nivolumab treatment.

This study was approved by the Institutional Review Board of Tongji Medical College of Huazhong University of Science and Technology. The patient gave his written informed consent for the collection of blood and tissue samples in accordance with the Declaration of Helsinki.

Immunohistochemistry
--------------------

The Dako PD-L1 IHC 22C3 pharmDx assay was used to detect PD-L1 protein expression in formalin-fixed paraffin-embedded (FFPE) tumor tissue slides. A four-tiered grading system was applied to evaluate the proportion of PD-L1 expression in tumor cells: TC0 for negative expression, TC1 for 1--5%, TC2 for 5--50%; TC3 for more than 50%.

Whole-Exome Sequencing and RNA Sequencing
-----------------------------------------

Whole-exome sequencing was carried out on the FFPE tumor tissue and matched normal samples. Peripheral blood was served as normal sample. Genomic DNAs were from tumor tissue, and blood was, respectively, extracted using the Qiagen DNA FFPE and Qiagen DNA blood mini kit (Qiagen). RNA was extracted from FFPE tumor tissue slides using RNeasy FFPE Kit (Qiagen). Sequencing libraries were constructed using Agilent SureSelect Human All Exon V6 kit (Agilent Technologies, USA), and sequencing procedures were performed on an Illumina HiSeq X-Ten platform with 150-bp paired-end reads. Raw reads were filtered using SOAPnuke (v1.5.6) to remove low-quality reads with unknown bases "N" more than 10%. Clean reads were aligned to the human reference genome (UCSCGRCh37/hg19) with the BWA (v0.7.12) for WES and RSEM (v1.3.0) for RNA sequencing. Somatic single-nucleotide variants (SNVs) and indels were identified using VarScan (v2.4.1) and subsequently filtered by an in-house approach to remove the possible false-positive variants ([@B46]). Aligned RNA reads were then analyzed using RSEM (v1.3.0). Tumor purity was evaluated computationally in paired samples using AscatNGS (v3.1.0) ([@B47]). Tumor mutational burden (TMB) was determined as the number of non-silent somatic mutations per megabase of exome examined. High and low TMB was determined according to a cut-off value of 10 and 2.5 muts/Mb, respectively. The expression of neoantigens was calculated according to both the variant allele frequency of corresponding mutations and the expression level of genes involved. Tumor neoantigen burden (TNB) was defined as the number of neoantigens per megabase of exome examined, and high TNB was determined according to a cut-off value of 4.5 neos/Mb.

HLA Typing and Neoantigen Prediction
------------------------------------

HLA typing of tumor samples and paired normal samples was assessed from WES results using POLYSOLVER (v1.0) and Bwakit (v0.7.11) ([@B48]), and were further used for neoantigen prediction. By using in-house software, all the non-silent mutations were translated into 21-mer peptide sequence centered on mutated amino acid. Then, the 21-mer peptide was used to create 9- to 11-mer peptide via a sliding window approach for predicting the binding affinity of major histocompatibility complex class I (MHC I) proteins and their peptide ligands. NetMHCpan (v3.0) was used to determine the binding strength of mutant peptides to patient-specific HLA alleles ([@B49]). The predicted peptides were scored according to the following indexes: strong binding affinity, mutation type, variant allele frequency, proteasomal C terminal cleavage, transporter associated with antigen processing, transporting efficiency, and gene expression. Peptides of score higher than 0 were selected. If selected peptides were generated from the same mutation, it can be only counted as one neoantigen.

*In vitro* PBMC Expansion
-------------------------

PBMCs were rested according to previous studies ([@B16], [@B50]). Autologous PBMCs (2 × 10^5^ cells per well) were co-cultured with separate peptides derived from candidate neoantigens (10 μg/ml) with RPMI-1640 supplemented with 10% fetal bovine serum, 10 U/ml of penicillin--streptomycin, 2 mmol/L L-glutamine, and 1× non-essential amino acid. Cell culture was conducted for 10 days at 37°C in a 5% CO~2~ atmosphere, and half of the culture media was replaced by fresh culture media containing 100 IU/ml IL-2, 50 ng/ml IL-7, and 50 ng/ml IL-15 on days 3, 5, and 7. Half of the culture media was replaced with fresh media without cytokines on day 9.

IFN-γ ELISPOT Assay
-------------------

The frequency of neoantigen-specific T cells after 10 days of coculture was determined by IFN-γ ELISPOT kit (Dakewei, China) ([@B51]). Briefly, PBMCs (2 × 10^5^ per well) and peptides (10 μg/ml) were added to triplicate wells. PBMCs cultured without peptides were regarded as the negative controls. Plates were scanned by Elispot Reader System (Cell Technology Inc., Columbia, MD), and the results were analyzed with Elispot software (AID, Strassberg, Germany).

TCR Sequencing
--------------

DNA extracted from PBMCs was prepared for TCR β-chain amplification using Short Read iR-Profile Reagent System HTBI-vc and sequenced using the NextSeq system. V-D-J gene segments in CDR3 sequences were identified by MiXCR (v2.1.10). Basic quantification of clonotypes was assessed with VDJ tools (v1.1.10). High-frequency clones were defined as T-cell clones with a frequency of ≥10^−3^. TCRs from simulated PBMCs were further analyzed by comparing the frequency of each T-cell clone being stimulated by the mutant peptide with the same clone being stimulated by the wild-type peptide. Neoantigen-specific T-cell clones were identified with an odd ratio higher than 10 and a value of *p* \< 0.01.

Statistics
----------

All the statistical analyses were conducted by GraphPad Prism version 8.0 (GraphPad Software, USA). TCR sequencing was compared using a one-sided Fisher\'s exact test. Other values were compared using an unpaired two-tailed Student\'s *t*-test. A value of *p* \< 0.05 was considered statistically significant.
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